ConductScience.org, home
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
API referenceFor AI assistants

Trial · NCT02565186

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 18 of 18

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Number of Participants With at Least 1 Treatment Emergent Adverse EventLasmiditan 100mg447Participants
Number of Participants With at Least 1 Treatment Emergent Adverse EventLasmiditan 200mg545Participants
Percentage of Migraine Attacks With Pain Freedom (PF) at 2 Hours After DoseLasmiditan 100mg26.7Percentage of PF Migraine Attacks
Percentage of Migraine Attacks With Pain Freedom (PF) at 2 Hours After DoseLasmiditan 200mg32.2Percentage of PF Migraine Attacks
Percentage of Migraine Attacks With Most Bothersome Symptom-Free (MBS) at 2 Hours After DoseLasmiditan 100mg37.2Percentage of MBS-Free Migraine Attacks
Percentage of Migraine Attacks With Most Bothersome Symptom-Free (MBS) at 2 Hours After DoseLasmiditan 200mg40.8Percentage of MBS-Free Migraine Attacks
Percentage of Participants With Medical Resource UtilizationLasmiditan 100mgVisit to cardiologist0.6Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 200mgVisit to cardiologist0.6Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 100mgVisit to primary care0.8Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 200mgVisit to primary care0.9Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 100mgVisit to Other providers0.1Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 200mgVisit to Other providers0.2Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 100mgHospitalized0.5Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 200mgHospitalized0.2Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 100mgProcedures performed0.8Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 200mgProcedures performed0.6Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 100mgER visits or visits to Physicians Office2.6Percentage of Participants
Percentage of Participants With Medical Resource UtilizationLasmiditan 200mgER visits or visits to Physicians Office2.6Percentage of Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02565186/results

API referenceFor AI assistants